Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21086438 | 0.94 | EPHX1 (0.62) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL24767707 | 0.94 | EPHX1 (0.62) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL25770309 | 0.94 | EPHX1 (0.62) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL25770264 | 0.94 | EPHX1 (0.61) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL25770259 | 0.92 | EPHX1 (0.59) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL13036243 | 0.89 | EPHX1 (0.59) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL13035805 | 0.89 | EPHX1 (0.59) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL4761484 | 0.89 | EPHX1 (0.59) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL3038208 | 0.87 | EPHX1 (0.64) | EPHX1MAPK1EPHX2NPC1RAB9A | |
| SCHEMBL16317723 | 0.87 | EPHX1 (0.64) | EPHX1MAPK1EPHX2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | EPHX1 422/4885MAPK1 3752/4885EPHX2 155/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | EPHX1 417/4885MAPK1 3889/4885EPHX2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.